INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 157 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q3 2023. The put-call ratio across all filers is 2.78 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2020 | $7,441,000 | -33.9% | 118,188 | +30.2% | 1.28% | -1.2% |
| Q4 2019 | $11,252,000 | +5.1% | 90,804 | -43.7% | 1.29% | +40.5% |
| Q3 2019 | $10,711,000 | -48.8% | 161,406 | -22.3% | 0.92% | -47.0% |
| Q4 2018 | $20,930,000 | -29.3% | 207,657 | -11.3% | 1.74% | +8.8% |
| Q3 2018 | $29,585,000 | -8.8% | 234,135 | -39.4% | 1.60% | -10.5% |
| Q2 2018 | $32,423,000 | +51.2% | 386,397 | +10.9% | 1.78% | +42.5% |
| Q1 2018 | $21,437,000 | – | 348,454 | – | 1.25% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Samsara BioCapital, LLC | 640,688 | $9,514,000 | 1.49% |
| CM Management, LLC | 45,000 | $668,000 | 0.50% |
| EULAV Asset Management | 660,000 | $9,801,000 | 0.26% |
| DLD Asset Management, LP | 225,200 | $3,346,000 | 0.24% |
| Virtus ETF Advisers LLC | 21,387 | $318,000 | 0.14% |
| GSA CAPITAL PARTNERS LLP | 79,145 | $1,175,000 | 0.12% |
| Hennion & Walsh Asset Management, Inc. | 136,720 | $2,030,000 | 0.11% |
| ALTRINSIC GLOBAL ADVISORS LLC | 168,800 | $2,507,000 | 0.08% |
| Inspire Investing, LLC | 31,868 | $473,000 | 0.06% |
| DUALITY ADVISERS, LP | 51,196 | $760,000 | 0.06% |